We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Propranolol Administration in Pediatric Patients With Recurrent Respiratory Papillomatosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01058317
Recruitment Status : Withdrawn (No participants enrolled)
First Posted : January 28, 2010
Last Update Posted : November 21, 2013
Sponsor:
Information provided by (Responsible Party):

January 27, 2010
January 28, 2010
November 21, 2013
January 2010
September 2010   (Final data collection date for primary outcome measure)
Decreased number of surgeries [ Time Frame: 3 months ]
Same as current
Complete list of historical versions of study NCT01058317 on ClinicalTrials.gov Archive Site
Improved voice quality [ Time Frame: 3 months ]
Same as current
Not Provided
Not Provided
 
Propranolol Administration in Pediatric Patients With Recurrent Respiratory Papillomatosis
Propranolol Administration in Pediatric Patients With Recurrent Respiratory Papillomatosis
Juvenile onset recurrent respiratory papillomatosis (JORRP) is a rare, difficult to treat, benign tumor of the pediatric airway. Current therapy is mainly surgical, but in a significant portion of patients adjuvant therapy is required to control the disease process. Although multiple adjuvant medical therapies have been tried, success has been limited. We have seen some success in a limited amount of patients using orally administered propranolol. Our goal is to enroll a larger cohort of patients to determine the effectiveness of propranolol as an adjuvant therapy for JORRP.
Not Provided
Interventional
Phase 2
Phase 3
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Recurrent Respiratory Papillomatosis
Drug: Propranolol
Propranolol 2mg/kg divided twice daily
Experimental: Children treated with propranolol
Intervention: Drug: Propranolol
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
September 2010
September 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • 1. Biopsy proven with appropriate Human Papilloma Virus typing Recurrent Respiratory Papilloma
  • 2. Child under age 10
  • 3. Informed consent and where appropriate informed assent
  • 4. Children who have undergone at least 4 documented surgical interventions in the past year.

Exclusion Criteria:

  • Parental or child refusal to participate
  • Heart failure
  • Atrio-ventricular heart block
  • Cardiac anomalies
  • Low resting heart rate
  • Low resting blood pressure
  • Wolff-Parkinson White Syndrome
  • Unexplained syncope
  • Asthma or Reactive airway disease
  • Renal or liver failure
  • Expected long fasting periods, >12 hours
  • Diabetes Mellitus
  • Hypersensitivity to propranolol
Sexes Eligible for Study: All
1 Year to 10 Years   (Child)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01058317
09-10-104
No
Not Provided
Not Provided
Massachusetts Eye and Ear Infirmary
Massachusetts Eye and Ear Infirmary
Not Provided
Principal Investigator: Christopher Hartnick, MD Massachusetts Eye and Ear Infirmary
Massachusetts Eye and Ear Infirmary
April 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP